Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
Armstrong, Andrew J., Halabi, Susan, Healy, Patrick, Alumkal, Joshi J., Winters, Carolyn, Kephart, Julie, Bitting, Rhonda L., Hobbs, Carey, Soleau, Colleen F., Beer, Tomasz M., Slottke, Rachel, Mundy,Мова:
english
Журнал:
European Journal of Cancer
DOI:
10.1016/j.ejca.2017.02.030
Date:
May, 2017
Файл:
PDF, 684 KB
english, 2017
File converter
Більше результатів пошуку
More benefits 
